Monoclonal antibodies against orthopoxviruses
AssigneeThe Gov. of the USA, as represented by The Secretary, Department of Health
InventorsZhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
Claims28
A substantially pure polypeptide comprising a fully human or humanized chimpanzee monoclonal antibody that binds B5 or A33 antigens or neutralizes Orthopoxviruses.
A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which anti-vaccinia virus B5 8AH8AL protein Fab fragment deposited with the ATCC as ATCC Accession No. PTA-7294 binds.
A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which anti-vaccinia virus A33 6C protein Fab fragment deposited with the ATCC as ATCC Accession No. PTA-7323 binds.
A substantially pure polypeptide comprising a monoclonal antibody that binds the antigen to which anti-vaccinia virus A33 12F protein Fab fragment deposited with the ATCC as ATCC Accession No. PTA-7324 binds.
An anti-vaccinia virus B5 8AH8AL deposited with ATCC as ATCC Accession No. PTA-7294.
An anti-vaccinia virus A33 6C deposited with ATCC as ATCC Accession No. PTA-7323.
An anti-vaccinia virus A33 12F deposited with ATCC as ATCC Accession No. PTA-7324.
Dependencies are inferred from the claim text.